<DOC>
	<DOCNO>NCT02387606</DOCNO>
	<brief_summary>The purpose study evaluate antiviral effect repeat oral dose JNJ 53718678 compare placebo healthy adult participant infected inoculation respiratory syncytial virus ( RSV ) -A Memphis 37b virus .</brief_summary>
	<brief_title>Study Evaluate Antiviral Activity , Safety , Pharmacokinetics Repeated Doses Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection</brief_title>
	<detailed_description>This randomize ( study medication assign participant chance ) , double-blind ( neither physician participant know identity assign treatment ) , placebo-controlled , single-center study JNJ 53718678 healthy adult participant . Study consist 3 phase : Screening ( Day -56 Study Day -3 prior plan date virus inoculation/challenge Study Day 0 ) , quarantine ( include challenge Day -1 -2 treatment 7 day ) , follow-up ( Day 15 28 ) . Participants admit quarantine unit Study Day -1 - 2 inoculate ( intranasal ) RSV-A Memphis 37b virus Study Day 0 . Participants evaluate 3 cohort : Cohort 1 Cohort 3 ( participant dose JNJ-53718678 placebo 7 day ) Cohort 2 ( 7 day [ Dosing Days 1-x ] [ x determine base result Cohort 1 ] ) . Participants randomize JNJ-53718678/placebo dosing start RSV presence nasal wash detect polymerase chain reaction ( PCR ) . After completion Cohort 1 , data review ( unblinded ) antiviral activity , safety , pharmacokinetic , clinical symptom mucus weight data evaluate , base Cohort 2 initiate . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Female participant must nonchildbearing potential : postmenopausal least 2 year surgically sterile otherwise incapable become pregnant Female participant , except postmenopausal woman , must negative serum pregnancy test screen Participants must agree comply contraceptive measure mention protocol Participants must serosuitable respiratory syncytial virus ( RSV ) within 57 day prior inoculation Participants must nonsmoker least one month prior screen participant must negative cotinine test screening Participants past history heart arrhythmia ( extrasystoli , tachycardia rest ) risk factor Torsade de Pointes syndrome Participants history evidence abuse alcohol , barbiturate , amphetamine , recreational narcotic drug use within past 3 month , Investigator 's opinion would compromise participant 's safety and/or compliance study procedures Participants current human immunodeficiency virus type 1 ( HIV1 ) HIV2 infection screen Participants current hepatitis A infection , hepatitis B virus ( HBV ) infection , hepatitis C virus ( HCV ) infection ( confirm HCV antibody ) screen Participants active acute respiratory infection admission ( Study Day 1 2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Respiratory Syncytial Virus Infections</keyword>
	<keyword>Placebo</keyword>
	<keyword>Antiviral activity</keyword>
	<keyword>JNJ-53718678</keyword>
</DOC>